clinical endpoint raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
== Awards == It was awarded Best Film, Best Director, Best Supporting Actress and Best Cinematography at the Thessaloniki Festival of Greek Cinema in 1970, as well as Best Foreign Film at the Hyères Festival, International Federation of Film Critics Special Mention at the 21st Berlin International Film Festival and Prix Georges-Sadoul in 1971.
Tomatoes were not grown in England until the 1590s. One of the earliest cultivators was John Gerard, a barber-surgeon. Gerard's Herbal, published in 1597, and largely plagiarized from continental sources, is also one of the earliest discussions of the tomato in England. Gerard knew the tomato was eaten in Spain and Italy. Nonetheless, he believed it was poisonous. Gerard's views were influential, and the tomato was considered unfit for eating for many years in Britain and its North American colonies. By 1820, tomatoes were described as "to be seen in great abundance in all our vegetable markets" and to be "used by all our best cooks", reference was made to their cultivation in gardens still "for the singularity of their appearance", while their use in cooking was associated with exotic Italian or Jewish cuisine. For example, in Elizabeth Blackwell's A Curious Herbal, it is described under the name "Love Apple (Amoris Pomum)" as being consumed with oil and vinegar in Italy, similar to consumption of cucumbers in the UK. In 1963, The New York Times gave an explanation of the name 'Love Apple' as a French misreading of the Italian pomo dei Mori ("the Moors' apple") as pomme d'amour, ("apple of love").
== Further reading == All the Birds of the World, Lynx Edicions, 2020. Del Hoyo, Josep; Elliott, Andrew; Sargatal, Jordi (eds.). Handbook of the Birds of the World (17-volume encyclopaedia), Lynx Edicions, Barcelona, 1992–2010. (Vol. 1: Ostrich to Ducks: ISBN 978-84-87334-10-8, etc.). Lederer, Roger; Carol Burr (2014). Latein für Vogelbeobachter: über 3000 ornithologische Begriffe erklärt und erforscht, aus dem Englischen übersetzt von Susanne Kuhlmannn-Krieg, Verlag DuMont, Köln, ISBN 978-3-8321-9491-8. National Geographic Field Guide to Birds of North America, National Geographic, 7th edition, 2017. ISBN 9781426218354 National Audubon Society Field Guide to North American Birds: Eastern Region, National Audubon Society, Knopf. National Audubon Society Field Guide to North American Birds: Western Region, National Audubon Society, Knopf. Svensson, Lars (2010). Birds of Europe, Princeton University Press, second edition. ISBN 9780691143927 Svensson, Lars (2010). Collins Bird Guide: The Most Complete Guide to the Birds of Britain and Europe, Collins, 2nd edition. ISBN 978-0007268146
The Act was last amended in the year 2009 and all the financial institutes are following this act. Till today there are 26 circulars issued by Bangladesh Bank under this act. To prevent money laundering, a banker must do the following:
== Epidemiology == The Hb Lepore trait has a worldwide distribution and may affect individuals of various ethnicities however the three main varieties which been defined tend to be more prevalent among specific ethnic groups, typically Caucasians of the Southern regions Central and Eastern Europe. The three main varieties are named for the geographical areas they were first identified in with various subtypes, the three main varieties are:
Sources: en.wikipedia.org
== List legend == Each group of radionuclides, starting with the longest-lived primordial radionuclides, is sorted by decreasing half-life, but the tables are sortable by other columns. All columns sort by usual lexicographical order; in the case of the nuclide column this gives order on the mass number A.
Releasing hormones and inhibiting hormones are hormones (signaling molecules) whose main purpose is to control the release of other hormones, either by stimulating or inhibiting their release. They are also called liberins () and statins () (respectively), or releasing factors and inhibiting factors. The principal examples are hypothalamic-pituitary hormones that can be classified from several viewpoints: they are hypothalamic hormones (originating in the hypothalamus), they are hypophysiotropic hormones (affecting the hypophysis, that is, the pituitary gland), and they are tropic hormones (having other endocrine glands as their target). For example, thyrotropin-releasing hormone (TRH) is released from the hypothalamus in response to low levels of secretion of thyroid-stimulating hormone (TSH) from the pituitary gland. The TSH in turn is under feedback control by the thyroid hormones T4 and T3. When the level of TSH is too high, they feed back on the brain to shut down the secretion of TRH. Synthetic TRH is also used by physicians as a test of TSH reserve in the pituitary gland as it should stimulate the release of TSH and prolactin from this gland. The main releasing hormones are as follows:
== United Nations agencies and related organizations == The United Nations focuses on five main areas: "maintaining peace and security, protecting human rights, delivering humanitarian aid, supporting sustainable development, and upholding international law". UN agencies, such as UN Relief and Works Agency, are generally regarded as international organizations in their own right. Additionally, the United Nations has Specialized Agencies, which are organizations within the United Nations System that have their member states (often nearly identical to the UN Member States) and are governed independently by them; examples include international organizations that predate the UN, such as the International Telecommunication Union, and the Universal Postal Union, as well as organizations that were created after the UN such as the World Health Organization (which was made up of regional organizations such as PAHO that predated the UN). A few UN special agencies are very centralized in policy and decision-making, but some are decentralized; for example, the country-based projects or missions' directors and managers can decide what they want to do in the fields. The UN agencies have a variety of tasks based on their specialization and their interests. The UN agencies provide different kinds of assistance to low-income countries and middle-income countries, and this assistance would be a good resource for developmental projects in developing countries.
Halliwell was awarded the Public Administration Medal (Silver) in 2010 by the President of Singapore for contributions to Singapore and awarded the President's Science and Technology Medal (2013) by the President of Singapore "for distinguished sustained and exceptional contributions to Singapore's Science and Engineering landscape". Halliwell was conferred the Outstanding Service Award at the NUS University Awards on 8 September 2023. In 2008, Halliwell was awarded the "Lifetime Achievement Award" by the Society for Free Radical Biology and Medicine in the US for overall sustained excellence in the field. He was described as a "Research Pioneer" by the journal Antioxidants & Redox Signaling in 2011. Same year, he was also awarded the Ken Bowman Research Award for outstanding achievements in the field of cardiovascular research from the Institute of Cardiovascular Sciences (Canada) and NUS University Award – Outstanding Researcher Award. He was elected a fellow of the American Association for the Advancement of Science in 2012. Halliwell was awarded a Doctor of Science honoris causa by King's College London in 2018. He was again identified as a "Highly Cited Scientist" for cross-disciplinary work by Clarivate Analytics in 2018. He was honoured as a Citation Laureate (2021) for "pioneering research in free-radical chemistry including the role of free radicals and antioxidants in human disease".
Sources: en.wikipedia.org
Cyclic peptides are polypeptide chains which contain a circular sequence of bonds. This can be through a connection between the amino and carboxyl ends of the peptide, for example in cyclosporin; a connection between the amino end and a side chain, for example in bacitracin; the carboxyl end and a side chain, for example in colistin; or two side chains or more complicated arrangements, for example in alpha-amanitin. Many cyclic peptides have been discovered in nature and many others have been synthesized in the laboratory. Their length ranges from just two amino acid residues to hundreds. In nature they are frequently antimicrobial or toxic; in medicine they have various applications, for example as antibiotics and immunosuppressive agents. Thin-Layer Chromatography (TLC) is a convenient method to detect cyclic peptides in crude extract from bio-mass.
Diff-Quik fixative reagent Triarylmethane dye Methanol Diff-Quik solution I (eosinophilic) Xanthene dye (Eosin Y) pH buffer Diff-Quik solution II (basophilic thiazine dyes) Methylene blue Azure A pH buffer
Although benzodiazepines are much safer in overdose than their predecessors, the barbiturates, they can still cause problems in overdose. Taken alone, they rarely cause severe complications in overdose; statistics in England showed that benzodiazepines were responsible for 3.8% of all deaths by poisoning from a single drug. However, combining these drugs with alcohol, opiates or tricyclic antidepressants markedly raises the toxicity. The elderly are more sensitive to the side effects of benzodiazepines, and poisoning may even occur from their long-term use. The various benzodiazepines differ in their toxicity; temazepam appears most toxic in overdose and when used with other drugs. The symptoms of a benzodiazepine overdose may include; drowsiness, slurred speech, nystagmus, hypotension, ataxia, coma, respiratory depression, and cardiorespiratory arrest. A reversal agent for benzodiazepines exists, flumazenil (Anexate), itself belonging to the chemical class of benzodiazepines. Its use as an antidote is not routinely recommended because of the high risk of resedation and seizures. In a double-blind, placebo-controlled trial of 326 people, 4 people had serious adverse events and 61% became resedated following the use of flumazenil. Numerous contraindications to its use exist. It is contraindicated in people with a history of long-term use of benzodiazepines, those having ingested a substance that lowers the seizure threshold or may cause an arrhythmia, and in those with abnormal vital signs.
Of the 66 cases of measles reported in the US in 2005, slightly over half were attributable to one unvaccinated individual who acquired measles during a visit to Romania. This individual returned to a community with many unvaccinated children. The resulting outbreak infected 34 people, mostly children and virtually all unvaccinated; 9% were hospitalized, and the cost of containing the outbreak was estimated at $167,685. A major epidemic was averted due to high rates of vaccination in the surrounding communities. In 2017, an outbreak of measles occurred among the Somali-American community in Minnesota, where MMR vaccination rates had declined due to the misconception that the vaccine could cause autism. The US Centers for Disease Control and Prevention recorded 65 affected children in the outbreak by April 2017.
=== 1990s: Early development of AI and open-source software === The concept of AI dates back to the mid-20th century, when computer scientists like Alan Turing and John McCarthy laid the groundwork for modern AI theories and algorithms. An early form of AI, the natural language processing "doctor" ELIZA, was re-implemented and shared in 1977 by Jeff Shrager as a BASIC program, and soon translated to many other languages. Early AI research focused on developing symbolic reasoning systems and rule-based expert systems. During this period, the idea of open-source software was beginning to take shape, with pioneers like Richard Stallman advocating for free software as a means to promote collaboration and innovation in programming. The Free Software Foundation, founded in 1985 by Stallman, was one of the first major organizations to promote the idea of software that could be freely used, modified, and distributed. The ideas from this movement eventually influenced the development of open-source AI, as more developers began to see the potential benefits of open collaboration in software creation, including AI models and algorithms. In the 1990s, open-source software began to gain more traction, the rise of machine learning and statistical methods also led to the development of more practical AI tools. In 1993, the CMU Artificial Intelligence Repository was initiated, with a variety of openly shared software.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.